Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

The Danish pharmaceutical giant Novo Nordisk, led by new CEO Maziar Mike Doustdar, is spearheading a radical transformation ...

Novo Nordisk, a global healthcare company, has announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet ...

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

Doctors caution that while Ozempic can help manage diabetes and obesity under medical supervision, misuse as a weight-loss shortcut may lead to nutritional deficiencies, muscle loss, and serious ...

Novo Nordisk has launched its blockbuster weight-loss drug Ozempic in India, beginning at INR 8,800 a month or four weeks ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more aggressive push to regain U.S. market share. “Wegovy (semaglutide) injection 0.25 ...

Novo Nordisk shares fell sharply after the Danish drugmaker said a pill with semaglutide, the key ingredient in its Ozempic and Wegovy blockbuster drugs for obesity and diabetes, didn't slow Alzheimer ...